• Equity PC Ratio   0.57
  • |
  • Index PC Ratio   1.14
  • |
  • Total PC Ratio   0.97
  • |
  • VIX PC Ratio   0.54
  • VIX 15.85
  • VXN 20.63
  • VXO 18.01
  • ISEE 85.00

TruCharts Trading Strategies and Stock Buy/Sell Reports
(Show Details)


Chart Settings
No saved settings found!

Chart Type:
From: / / To: / /
Show detail in :
 Chart Skins:      
Price Overlays:





Indicator Windows:





NO
Refresh      
NVAX (Novavax Inc.)
Last Trade 6.12 Dividend/Share 0 PE Ratio -12
Date May 24-2019 Dividend Yield 0.000 Return on Assets -73.03
Change 0 ExDividend Date 0 Return on Capital null
Bid 0 Latest EPS -10.2 Price/Sale 5.020
Ask 0 LatestEPS Date 2018-12-31 Price to Book null
Volume 43925 EPS ttm -0.510 Institutional % 43.4
Avg Volume 1.01M Shares Outstanding 23.47M Insider % null
Open 6.14 Float 20.21M Short Ratio null
Prev Close 6.12 Return On Equity 145.32 5 Year Change % -0.940
High 6.163 Consensus EPS -0.12 2 Year Change % -0.700
Low 5.92 No. of Estimate 4.000 1 Year Change % -0.822
52 Week High 51.6 EPS Surprise $ null YTD Change % -0.845
52 Week Low 5.72 EPS Surprise Percent 0 6 Month Change % -0.835
52 Week Change -82.000 EBITDA 0M 3 Month Change % -0.849
50 Day MA 9.66028 Revenue 0M 1 Month Change % -0.402
200 Day MA Gross Profit 0M 5 Day Change % 0.013
Market Cap 143.65M Cash 0M 30 Day Change % -0.434
Beta 2.216478 Debt 0M Stock Exchange Nasdaq Global Select
Sector Healthcare Revenue Per Share 0 Short Interest 0
Short Date 0 Revenue Per Employee 0 Short Ratio null
Data courtesy of IEX
Company Profile

Novavax, Inc., a clinical-stage biopharmaceutical company, focuses on developing recombinant vaccines for infectious diseases using its virus-like particle platform technology. Its vaccine product candidates target pandemic influenza, including H1N1 and H5N1 strains; seasonal influenza; Respiratory Syncytial Virus; and Varicella Zoster Virus that causes shingles. The company has a joint venture with Cadila Pharmaceuticals Ltd. to develop and commercialize seasonal influenza and H1N1 pandemic vaccine candidates, Cadila?s biogeneric products, and other diagnostic products for the territory of India. It also has a co-marketing agreement with GE Healthcare for a pandemic influenza vaccine solution. The company was founded in 1987 and is headquartered in Rockville, Maryland.